The gray areas have not been assigned to any hospital referral regions (HRRs) based on the HRR definition used by the Dartmouth Atlas (https://www.dartmouthatlas.org/downloads/atlases/96Atlas.pdf).
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Kunst N, Long JB, Xu X, et al. Use and Costs of Breast Cancer Screening for Women in Their 40s in a US Population With Private Insurance. JAMA Intern Med. Published online March 23, 2020. doi:10.1001/jamainternmed.2020.0262
Although professional society guidelines vary, most private insurance companies in the US will reimburse for the costs of mammography for women age 40 through 49 years.1 While the clinical benefits and harms of screening women in their 40s have been widely discussed,2,3 there is limited evidence regarding the cost implications of contemporary breast cancer–screening practices among this population. We estimated annual breast cancer screening–associated costs among US women in their 40s who have private insurance. We also assessed regional variation in these costs.
We conducted a retrospective study of women aged 40 through 49 years who had private insurance using data from the Blue Cross Blue Shield Axis, a large commercial claims database accessed via a secure portal. We selected women between ages 40 and 49 years who were eligible to receive a screening mammography in 2017 and identified screening mammography in 2017 using a validated algorithm and relevant Current Procedural Terminology codes.4 For each beneficiary screened, we identified subsequent evaluation tests in the 4 months after the initial screening mammography and calculated the total annual cost of screening based on use and unit costs of initial screening (2-dimensional mammography with or without digital breast tomosynthesis [DBT]), supplementary screening (screening ultrasonography), recall (diagnostic 2-dimensional mammography with or without DBT and ultrasonography), and other diagnostic tests (magnetic resonance imaging and biopsy). We then estimated the mean cost per beneficiary screened.
To estimate national screening costs, using a previously applied approach,5 we multiplied the total national number of women with private insurance who were aged 40 through 49 years and eligible for breast cancer screening by the proportion of women screened and the mean per-beneficiary-screened cost of screening derived from our study. To examine regional variation, we estimated the mean total per-beneficiary-screened cost for each hospital referral region (HRR), and evaluated variation in these estimates across HRRs (eAppendix in the Supplement). The Human Investigation Committee of Yale School of Medicine approved this study as exempt (in a category for research with deidentified secondary data); thus, informed consent was not needed. Analyses were performed using SQL Server Management Studio version 17.0 (Microsoft), STATA/MP version 14.1 (StataCorp), and R version 3.5.3 (R Foundation for Statistical Computing).
Our study cohort included 2 257 393 women aged 40 to 49 years. Of these women, 930 526 (41.2%) were screened with mammography in 2017, 543 380 (24.1%) with 2-dimensional mammography, and 387 146 (17.2%) with DBT (Table). Among the 930 526 women who had a screening mammography during the study period (either with or without DBT), 137 764 (14.8%) were recalled for diagnostic evaluation and 20 229 (2.2%) were referred for other diagnostic tests (Table).
The mean cost of breast cancer screening was $353 per beneficiary screened (Table). The main contributor to this mean (SD) cost was initial screening mammography (mean [SD] per-person cost, $249 [$125]) followed by recall (mean [SD] per-person cost, $56 [$172]) and other diagnostic tests (mean [SD] per-person cost, $45 [$421]). The median cost of breast cancer screening was $250 (interquartile range, $174-367) per beneficiary screened (Table). When extrapolating these costs to the population who have private insurance in the US, the total national cost of screening women in their 40s was $2.13 billion per year, most of which was accounted for by the initial screening mammography ($1.50 billion; Table).
There was substantial regional variation in breast cancer screening costs. The total annual mean (SD) costs of breast cancer screening varied from $151 ($258) to $751 ($1100) per beneficiary screened across HRRs (Figure).
We found that although fewer than half of the women aged 40 through 49 years who had private insurance and were eligible received annual breast cancer screening in 2017, the estimated annual national cost was $2.13 billion. These costs are borne despite the unclear tradeoff between clinical benefits and risks of screening women aged 40 through 49 years. Furthermore, the cost per beneficiary screened varied 5-fold across regions. Of note, the costs identified in this study were substantially higher than estimates used in previous cost analyses (eg, 2-dimensional mammography unit cost: $213 in this study, compared with $140-$155 in prior studies).5,6 Our data add clarity around the costs of breast cancer screening for women in their 40s, drivers of these costs, and magnitude of regional variation. They can help inform policy-makers’ decisions and future cost-effectiveness evaluations to optimize resource allocation.
Accepted for Publication: January 25, 2020.
Corresponding Author: Natalia Kunst, MSc, Department of Health Management and Health Economics, Institute of Health and Society, Faculty of Medicine, University of Oslo, PO Box 1089, Blindern, Oslo 0317, Norway (email@example.com; firstname.lastname@example.org).
Published Online: March 23, 2020. doi:10.1001/jamainternmed.2020.0262
Author Contributions: Dr Long had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Kunst, Busch, Kyanko, Gross.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Kunst.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Kunst, Long, Busch.
Administrative, technical, or material support: Kunst, Kyanko, Gross.
Conflict of Interest Disclosures: Ms Kunst reported funding from the Research Council of Norway (276146 and 304034) and Link Medical Research during the conduct of the study. Dr Xu reported receiving research support through Yale University from the Centers for Medicare & Medicaid Services to develop and maintain performance measures, and research grants from the American Cancer Society, the National Institutes of Health, and the Agency for Healthcare Research and Quality during the conduct of the study. Dr Busch reported receiving research grants from the National Institute of Health, the Robert Wood Johnson Foundation, the Donaghue Foundation, and the American Cancer Society during the conduct of this study. Dr Kyanko reported receiving research support through Yale University from the Centers for Medicare & Medicaid Services to develop and maintain hospital performance measures during the conduct of the study. Dr Richman reported receiving grants from the National Institutes of Health/National Center for Advancing Translational Sciences during the conduct of the study and personal fees from the Centers for Medicare & Medicaid outside the submitted work. Dr Gross reported receiving a research grant National Comprehensive Cancer Network/Pfizer, funding from Johnson & Johnson to assist with developing new approaches to sharing clinical trial data (through the Yale Open Data Access Project), and funding from Flatiron Inc for travel and speaking outside the submitted work. No other disclosures were reported.
Funding/Support: Funding for this work was provided the National Institutes of Health/National Center for Advancing Translational Sciences (grant KL2 TR001862 [Dr Richman]) and the American Cancer Society (grant RSGI-15-151-01 [Dr Gross]). Ms Kunst's effort on this work was funded by the Research Council of Norway and LINK Medical Research (grants 276146 and 304034).
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Create a personal account or sign in to: